Literature DB >> 12879274

High prevalence of asymptomatically poor muscle perfusion of lower extremities measured in systemic lupus erythematosus patients with abnormal myocardial perfusion.

C C Lin1, H J Ding, Y W Chen, J J Wang, S T Ho, A Kao.   

Abstract

Patients with systemic lupus erythematosus (SLE) may develop premature atherosclerosis, notably peripheral vascular disease (PVD) presenting with intermittent claudication or gangrene. Therefore, it is important to investigate if high prevalence of poor muscle perfusion of lower extremities in SLE patients with abnormal myocardial perfusion is related to more cardiovascular risk factors. We used a well-established and noninvasive radionuclide method (xenon 133 muscle washout) to evaluate objectively the anterior tibial muscle perfusion of 34 SLE female patients without symptoms/signs of PVD in the lower extremities. The patients were separated into two groups according to myocardial perfusion imaging results. Meanwhile, 30 normal female controls with matched age distribution were also included for comparison. The muscle perfusion differed significantly ( P <0.05) between patients (1.90+/-0.41 ml/100 g per min) and controls (2.91+/-0.50 ml/100 g per min), as well as between 18 SLE patients with abnormal myocardial perfusion (1.33+/-0.43 ml/100 g per min) and 16 with normal myocardial perfusion (2.26+/-0.45 ml/100 g per min). Based on the xenon 133 muscle washout method, we conclude that muscle perfusion in the lower extremities of SLE patients without symptoms/signs of PVD is significantly decreased and related to abnormal myocardial perfusion.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12879274     DOI: 10.1007/s00296-003-0353-9

Source DB:  PubMed          Journal:  Rheumatol Int        ISSN: 0172-8172            Impact factor:   2.631


  13 in total

1.  Effects of smoking on pulmonary uptake of technetium-99m methoxyisobutylisonitrile during myocardial perfusion imaging.

Authors:  C H Kao; Y Y Shen; J K Lee
Journal:  J Nucl Cardiol       Date:  1999 Jan-Feb       Impact factor: 5.952

2.  Peripheral ischemia and collagen disease: clinical manifestations, diagnosis, and treatment.

Authors:  R G DePalma; R W Moskowitz; W D Holden
Journal:  Arch Surg       Date:  1972-08

3.  Coronary atherosclerosis and myocardial infarction associated with systemic lupus erythematosus.

Authors:  V G Tsakraklides; L C Blieden; J E Edwards
Journal:  Am Heart J       Date:  1974-05       Impact factor: 4.749

4.  The bimodal mortality pattern of systemic lupus erythematosus.

Authors:  M B Urowitz; A A Bookman; B E Koehler; D A Gordon; H A Smythe; M A Ogryzlo
Journal:  Am J Med       Date:  1976-02       Impact factor: 4.965

5.  The role of technetium-99m sestamibi myocardial perfusion single-photon emission computed tomography (SPECT) in the detection of cardiovascular involvement in systemic lupus erythematosus patients with non-specific chest complaints.

Authors:  S S Sun; Y C Shiau; S C Tsai; C C Lin; A Kao; C C Lee
Journal:  Rheumatology (Oxford)       Date:  2001-10       Impact factor: 7.580

6.  [The evaluation of blood perfusion of lower extremities in patients with NIDDM by 133Xe muscle clearance test: a preliminary report].

Authors:  C T Tsou; C H Kao; W Y Lin; M D Chen; S J Wang; W H Lin; L T Ho
Journal:  Zhonghua Yi Xue Za Zhi (Taipei)       Date:  1993-03

7.  Peripheral vascular disease in patients with systemic lupus erythematosus.

Authors:  J McDonald; J Stewart; M B Urowitz; D D Gladman
Journal:  Ann Rheum Dis       Date:  1992-01       Impact factor: 19.103

8.  The 1982 revised criteria for the classification of systemic lupus erythematosus.

Authors:  E M Tan; A S Cohen; J F Fries; A T Masi; D J McShane; N F Rothfield; J G Schaller; N Talal; R J Winchester
Journal:  Arthritis Rheum       Date:  1982-11

9.  Outcome measures to be used in clinical trials in systemic lupus erythematosus.

Authors:  V Strand; D Gladman; D Isenberg; M Petri; J Smolen; P Tugwell
Journal:  J Rheumatol       Date:  1999-02       Impact factor: 4.666

10.  Vascular manifestations of systemic lupus erythematosus.

Authors:  A Ansari; P H Larson; H D Bates
Journal:  Angiology       Date:  1986-06       Impact factor: 3.619

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.